USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/4707
Title: Realizări şi perspective în tratamentul diabetului zanarat tip 2
Other Titles: The realisations and perspectives in diabetes mellitus treatment
Authors: Bacinschi, Nicolae
Ghicavîi, Victor
Baltag, Natalia
Bacinschi, Aurelia
Morneală, Elena
Issue Date: 2012
Publisher: CEP "Medicina"
Citation: BACINSCHI, Nicolae, GHICAVÎI, Victor et al. Realizări şi perspective în tratamentul diabetului zanarat tip 2. In: Anale Științifice ale IP USMF “Nicolae Testemiţanu”. Ed. a 13-a. Chișinău: CEP Medicina, 2012, Vol. 1: Probleme medico-biologice şi farmaceutice, pp. 187-195.
Abstract: The rational selection of oral antidiabetics in diabetes mellitus treatment, type II is determined by the influence upon pathogenic way, prevention of insulinoresistance and insulin secretion insufficiency. With this purpose theare can be utilized sulphonylureics (glyclazide, glypizide, glymepiride etc.), biguanides (metphormine), meglytinedes (repaglynide, nateglynide, mitiglynide), thyazolidindiones (pioglytazone, balaglyztazone, rivoglitazone etc.), dual/pan PPAR modulators ( tesaglitazar, muraglitazar, aleglitazar, chiglitazar etc.), tetrazaharides (acarboze, vogliboze etc.), GLP-1 agonists (exenatide, exenatide LAR, liraglutide, albiglutide etc.), DPP-IV antagonists and blockers (sitaglypide, vildaglyptide, saxaglyptine, aloglyptine), amilines analogues (pramlintid), selective sodium glucose cotransporter-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin etc.), 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors (INCB13739), situins (resveratrol etc.), AMP-activated protein kinase (imeglimin etc.), glucokinase activators (piragliatin etc.), agonists D2-receptors (bromcriptine), bile acid sequestrants (coleselevam) etc.. Selectarea raţională a antidiabeticelor orale în tratamentul diabetului zaharat tip 2 este determinată de influenţa asupra verigelor patogenetice, combaterea insulinorezistenţei şi insuficienţei secreţiei insulinei. Cu acest svop se pot utiliza: sulfonilureicele (gliclazida, glipizida, glimepirida etc.), biguanidele (metformina), meglitinidele (repaglinida, nateglinida, mitiglinida), tiazolidindionele (pioglitazon, balaglitazon, rivoglitazon etc.), modulatorii bi-şi pan ai PPAR receptorilor (tesaglitazar, muraglitazar, aleglitazar, cicglitazar etc.), tetrazaharidele (acarboza, vogliboza etc.), agoniştii GLP-1 (exenatid, exenatid LAR, liraglutid, albiglutid etc.), antagoniştii sau blocantele DPP-IV (sitagliptina, vildagliptina, saxagliptina, alogliptina etc.), analogii amilinei (pramlintid), inhibitorii sodiu-glucoză cotransportorului 2 (dalagliflozin, canagliflozin, empagliflozin etc.), inhibitorii 11-beta-hidroxisteroid dehidrogenazei 1 (INCB13739), sirtuinele (resveratrol etc.), activatorii AMP-protein kinazei (imeglimin etc.), activatorii glucokinazei (piragliatin etc.), agoniştii D2-receptorilor (bromocriptina etc.), sechestranţii acizilor biliari (coleselevam etc.) etc..
URI: http://repository.usmf.md/handle/20.500.12710/4707
Appears in Collections:Farmacologie și farmacologie clinică

Files in This Item:
File Description SizeFormat 
REALIZARI_SI_PERSPECTIVE_IN_TRATAMENTUL_DIABETULUI_ZANARAT_TIP_2.pdf274.81 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback